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Clinical PerspectiveWhat Is New?Detrimental effects of vitamin K antagonists on vascular and cardiac phenotypes of subclinical cardiovascular disease were observed in a large population‐based cohort.The analysis demonstrated a relationship of vitamin K antagonists treatment with increased arterial stiffness, higher left ventricular mass, and decreased cardiac systolic function independent of the concomitant clinical profile.What Are the Clinical Implications?Noncanonical effects of vitamin K antagonists merit critical consideration against the background of frequently coprevalent atherosclerosis and cardiovascular disease and may be relevant for the long‐term management of patients with oral anticoagulation.Evaluating the findings in contrast to the treatment with direct‐acting oral anticoagulants will be crucial to develop clinical implications for an individualized anticoagulation therapy.

Introduction {#jah33437-sec-0008}
============

Vitamin K antagonists (VKA) are recommended to patients with an indication for oral anticoagulation therapy to prevent thromboembolic complications.[1](#jah33437-bib-0001){ref-type="ref"} Recent data imply that the intake of VKA involves effects beyond the well‐known inhibition of the vitamin K--dependent coagulation factors (F) II, VII, IX, and X.[2](#jah33437-bib-0002){ref-type="ref"} Experimental data suggest that VKA may decrease the activity of the vitamin K--dependent proteins matrix GIa protein (MGP) and growth arrest--specific gene 6 (Gas‐6) by inhibiting the γ‐carboxylation process.[3](#jah33437-bib-0003){ref-type="ref"} Unlike coagulation factors, which are synthesized and carboxylated within the liver, MGP and Gas‐6 are carboxylated within the vasculature.[4](#jah33437-bib-0004){ref-type="ref"} Increased levels of undercarboxylated MGP have been associated with vascular calcification.[5](#jah33437-bib-0005){ref-type="ref"} The deficiency of active MGP and Gas‐6 provokes cell death, decreased contractility of vascular smooth muscle cells, and accelerated vascular calcification.[4](#jah33437-bib-0004){ref-type="ref"}, [6](#jah33437-bib-0006){ref-type="ref"} Studies have also demonstrated that VKA therapy is associated with vascular calcification.[7](#jah33437-bib-0007){ref-type="ref"}, [8](#jah33437-bib-0008){ref-type="ref"} Given the important role of vascular calcification in the pathophysiology of vascular stiffness and the correlation of calcification with increased serum levels of inflammatory markers, hypertension, and incident cardiovascular disease (CVD), VKA may exert clinically relevant noncoagulant effects.[9](#jah33437-bib-0009){ref-type="ref"}

Since alternatives to VKA therapy are available for most indications, noncoagulant effects of VKAs on the development and progression of atherosclerosis and CVD may have clinically relevant implications.

Against this background, the present study investigated the interrelation between the intake of VKA and the progress and development of CVD in the setting of a large population‐based cohort study.

Methods {#jah33437-sec-0009}
=======

The analysis presents clinical data of a large‐scale population‐based cohort with ongoing follow‐up examinations. This project constitutes a major scientific effort with high methodological standards and detailed guidelines for analysis and publication to ensure scientific analyses on highest level. Therefore, data are not made available for the scientific community outside the established and controlled workflows and algorithms. To meet the general idea of verification and reproducibility of scientific findings, we offer access to data at the local database in accordance with the ethics vote upon request at any time. The GHS (Gutenberg Health Study) steering committee, which comprises a member of each involved department and the head of the GHS, convenes once a month. The steering committee decides on internal and external access of researchers and use of the data and biomaterials based on a research proposal to be supplied by the researcher. Interested researchers make their requests to the head of the GHS (Philipp S. Wild; <philipp.wild@unimedizin-mainz.de>).

Study Sample {#jah33437-sec-0010}
------------

We investigated data of 15 010 individuals (age range 35--74 years) enrolled in the GHS, a population‐representative, prospective, observational, single‐center cohort study in the Rhine‐Main region in Midwestern Germany. Participants were enrolled between April 2007 and April 2012 and underwent a detailed 5‐hour medical--technical examination in the study center. The sample was drawn randomly from the local registration offices with equal strata for sex, residence (urban and rural), and age decades. Details of the study design have been published elsewhere.[10](#jah33437-bib-0010){ref-type="ref"} The study complies with the principles outlined in the Declaration of Helsinki. The study protocol, study documents, and sampling design were approved by the Ethics Committee of the State Chamber of Physicians of Rhineland‐Palatinate, Germany (reference number 837.020.07(5555)) and by local institutional review boards. All study participants provided written informed consent.

Data Assessment {#jah33437-sec-0011}
---------------

For the current analysis, information was obtained during the baseline visit at the study center. All study participants underwent comprehensive cardiovascular phenotyping at the study platform (see Data [S1](#jah33437-sup-0001){ref-type="supplementary-material"} for a detailed description of definitions for traditional cardiovascular risk factors and comorbidities used in the present analysis). Current medication use including medication on demand was recorded digitally by scanning the drug identification bar code from drug packages or alternatively established on the basis of self‐reported information from participants (eg prescription plan). History of drug intake and the type of prescription (self‐medication versus prescription by a physician) were recorded for the medication. Central pharmaceutical numbers were translated into the Anatomical Therapeutic Chemical code of the current pharmaceutical index. Individuals with regular or current VKA use (Anatomical Therapeutic Chemical Code: B01AA) were defined as users and nonusers as the reference group.

Laboratory Analyses {#jah33437-sec-0012}
-------------------

Routine laboratory parameters (ie blood glucose, creatinine, lipids, fibrinogen, and blood count) were measured using standardized methods from fresh venous blood samples in all 15 010 study participants at enrollment in the central laboratory of the University Medical Center. For biobanking, samples were aliquoted and stored at −80°C immediately after blood draw. Specific biomarkers were analyzed in the subsample of the first 5000 participants: midregional pro‐atrial natriuretic peptide (BRAHMS AG), midregional pro‐adrenomedullin (BRAHMS AG), N‐terminal pro B‐type natriuretic peptide (Roche Diagnostics), high‐sensitivity (hs) D‐dimer (Instrumentation Laboratory), thrombomodulin (Sekisui Diagnostics), high‐sensitivity C‐reactive protein (hs‐CRP) (Abbott), IL‐18 (MBL), IL‐1 receptor antagonist (R&D Systems), and myeloperoxidase (Prognostix) levels were measured using commercially available assays according to the manufacturer\'s recommendation. FII, FVII, FVIII, FIX, FX, FXI, tissue factor, and von Willebrand factor measurements were performed on a Siemens BCS‐XP device. Collection, processing, handling, and storage of blood specimens were performed according to specific standard operating procedures.

Single Nucleotide Polymorphisms for VKA Metabolism {#jah33437-sec-0013}
--------------------------------------------------

Single selected single nucleotide polymorphisms (SNPs) in the presently available genetic variant data set were used for this analysis. Detailed description of SNP selection is given in the Supplemental Material. Genetic information was available from 4175 of the first 5000 subjects enrolled. Genome‐wide genotyping was performed using Affymetrix Genome‐Wide Human SNP array 6.0 (Affymetrix, Santa Clara, CA), which assays 925.939 SNPs. SNPs contributing to the dose variability of vitamin K antagonists were selected from the genome‐wide association studies catalogue (<https://www.ebi.ac.uk/gwas/>) maintained by the National Human Genome Research Institute using the following search terms: "warfarin," "phenprocoumon," "anticoagulants," and "vitamin K antagonist".

Data Management and Statistical Analysis {#jah33437-sec-0014}
----------------------------------------

A central data management unit was in charge of quality control including the performance of plausibility tests and review for completeness by predefined algorithms. Descriptive statistics were generated for all variables. For comparisons of binary and continuous variables, prevalence ratios and relative differences were calculated, respectively. In linear regression models, surrogate parameters of clinical and subclinical CVD were related to VKA treatment. Skewness was evaluated by density plot and log‐transformed where appropriate. Covariates were selected on the basis of known cardiovascular risk factors and significant findings from the univariate analysis. Linear regression models were used to screen for interaction by including the interaction terms age×VKA and sex (women)×VKA in the model. Since antihypertensive drugs and statins are known to influence cardiovascular function and structure, multivariable linear models were adjusted accordingly. To evaluate a potential time‐dependent effect of VKA use on surrogate markers of CVD, VKA treatment was stratified according to treatment length with a cutoff point of 3 years. To investigate a homogeneous subsample of VKA users, a subgroup analysis was conducted in the individuals diagnosed with atrial fibrillation and a CHA~2~DS~2~‐VASc score of ≥1 (as such an indication for treatment with oral anticoagulation). Inverse probability of treatment weighting using the propensity score was performed in individuals with diagnosed atrial fibrillation/venous thromboembolism only under consideration of the cardiovascular profile (ie presence of traditional cardiovascular risk factors and history of cardiovascular diseases). Multivariable regression models with surrogate markers of CVD as dependent variables were conducted to investigate their relationship with SNPs encoding genes involved in the metabolism of VKA (as independent variable). Because of the explorative character of the analysis, a significance threshold was not defined for *P* values. *P* values were interpreted as continuous measure of statistical evidence. Statistical data analyses were conducted using the software program R, version 3.3.1 (<http://www.r-project.org>).

Results {#jah33437-sec-0015}
=======

Comparisons of Clinical and Biochemical Characteristics According to VKA Intake {#jah33437-sec-0016}
-------------------------------------------------------------------------------

Of 15 010 study participants, 287 (1.9%) received VKA (282 phenprocoumon and 5 warfarin) at the time of examination. A total of 159 subjects were excluded from the analysis (156 individuals with missing information on medication intake and 3 individuals receiving novel, direct‐acting anticoagulants), resulting in a sample size of 14 851 individuals for the present analysis. Table [1](#jah33437-tbl-0001){ref-type="table"} displays cardiovascular risk factors and comorbidities according to VKA use. Subjects with current VKA use were about 12 years older and more likely to be male. As expected, VKA users had a higher cardiovascular burden. The strongest inequalities in prevalence were seen for the entities with indication for treatment with oral anticoagulation, atrial fibrillation, and pulmonary embolism. The smallest differences were observed for current smoking and family history of myocardial infarction or stroke. With regard to indication for oral anticoagulation therapy, the majority of study participants (58.1%) had atrial fibrillation, followed by venous thromboembolism (33.1%). Subjects with oral anticoagulation were more likely to be using antidiabetic medications, antihypertensive drugs, diuretics, and lipid‐modifying drugs. The intake of antiplatelet drugs did not differ between both groups (9.1% and 10.3% for VKA users and nonusers, respectively; Table [S1](#jah33437-sup-0001){ref-type="supplementary-material"}).

###### 

Cardiovascular Risk Profile of the Study Sample According to VKA Intake

                                                          No Intake of VKA (N=14 564)   Intake of VKA (N=287)
  ------------------------------------------------------- ----------------------------- -----------------------
  Age, y                                                  55.0 (46.0/64.0)              67.0 (61.0/71.0)
  Sex (female), % (n)                                     50.0 (7282)                   30.3 (87)
  Traditional cardiovascular risk factors, % (n)                                        
  Diabetes mellitus                                       7.4 (1069)                    18.2 (52)
  Dyslipidemia                                            29.3 (4257)                   42.7 (122)
  Family history of myocardial infarction and/or stroke   22.1 (3221)                   24.0 (69)
  Hypertension                                            49.5 (7208)                   72.5 (208)
  Obesity                                                 25.0 (3638)                   41.6 (119)
  Smoking                                                 19.5 (2834)                   14.8 (42)
  Comorbidities, % (n)                                                                  
  Atrial fibrillation                                     2.2 (315)                     58.1 (161)
  Cancer                                                  9.0 (1305)                    16.8 (48)
  Chronic kidney disease                                  3.1 (450)                     14.7 (42)
  Chronic obstructive pulmonary disease                   5.0 (721)                     8.7 (25)
  Congestive heart failure                                1.1 (158)                     14.0 (40)
  Coronary artery disease                                 4.1 (582)                     21.3 (58)
  Deep vein thrombosis                                    3.4 (498)                     28.6 (80)
  Liver disease                                           0.7 (107)                     1.0 (3)
  Myocardial infarction                                   2.7 (394)                     15.7 (44)
  Peripheral artery disease                               3.1 (448)                     18.4 (52)
  Peripheral vascular bypass surgery                      0.2 (31)                      6.3 (18)
  Pulmonary embolism                                      0.1 (13)                      4.5 (13)
  Stroke                                                  1.6 (238)                     14.4 (40)

Data are expressed as the relative and absolute frequencies for binary variables, for continuous variables as median with 25th/75th percentiles. Information on medication‐based Anatomical Therapeutic Chemical code was available for 14 851 individuals. A total of 3 individuals received direct‐acting anticoagulants and were therefore excluded from the analysis. VKA indicates vitamin K antagonists.

Surrogate markers of clinical and subclinical CVD according to VKA intake are summarized in Table [2](#jah33437-tbl-0002){ref-type="table"}. As expected from the clinical characteristics, subjects with VKA treatment had a higher augmentation index, stiffness index, baseline brachial artery diameter, intima‐media thickness, E/E′‐ratio, left ventricular (LV) mass/height^2.7^ and relative wall thickness as well as lower flow‐mediated dilatation, reactive hyperemia index, and LV ejection fraction compared with individuals not taking VKA.

###### 

Surrogate Parameters of Clinical and Subclinical Cardiovascular Disease

                                                                                                No Intake of VKA (N=14 564)
  ----------------------------------------------------------------------- --------------------- -----------------------------
  Vasculature                                                             Arterial stiffness    
  Augmentation index, %[a](#jah33437-note-0004){ref-type="fn"}            14.43 (3.12/29.03)    16.73 (6.74/31.48)
  Stiffness index, m/s                                                    7.29 (5.78/9.13)      7.72 (6.36/9.26)
  Endothelial function                                                                          
  Flow‐mediated dilation, %                                               7.4 (4.6/10.9)        6.0 (3.6/8.4)
  log (reactive hyperemia index)[b](#jah33437-note-0005){ref-type="fn"}   0.67 (0.33/0.94)      0.41 (0.13/0.78)
  Reflection index                                                        68 (55/77)            69 (57/78)
  Endothelial structure                                                                         
  Baseline BA diameter, mm                                                4.32 (3.68/4.94)      4.81 (4.19/5.33)
  Intima‐media thickness, mm[c](#jah33437-note-0006){ref-type="fn"}       0.63 (0.56/0.73)      0.72 (0.66/0.85)
  Peripheral arterial disease                                                                   
  Ankle‐brachial index                                                    0.99 (0.93/1.04)      0.97 (0.88/1.06)
  Heart                                                                   Cardiac function      
  Diastolic function---E/E′ ratio                                         7.18 (5.90/8.94)      8.33 (6.57/11.31)
  Systolic function---LV ejection fraction, %                             63.5 (60.0/67.1)      60.8 (55.0/65.4)
  Cardiac structure                                                                             
  LV mass/height^2.7^, g/m^2.7^                                           36.5 (30.7/43.5)      45.9 (38.6/55.6)
  Relative wall thickness                                                 0.395 (0.345/0.455)   0.424 (0.366/0.490)

For continuous variables, data are expressed as median with 25th/75th percentile. Data were available in \>85% of participants, unless otherwise indicated. BA indicates brachial artery; LV, left ventricular; VKA, vitamin K antagonists.

Measured in a sample of 11 250 participants.

Measured in a sample of 10 512 participants.

Measured in a sample of the first 5000 participants.

Accordingly, the concentrations of biomarkers related to cardiac function were higher in anticoagulated compared with nonanticoagulated subjects and there was greater inflammatory activity, as strongly reflected by the elevated concentration of hs‐CRP. As proof for the VKA drug effect, activity of vitamin K‐dependent coagulation factors was reduced in VKA users and concentrations of hs‐D‐dimer were ≈50% lower than in VKA‐naïve participants (Tables [S2](#jah33437-sup-0001){ref-type="supplementary-material"} and [S3](#jah33437-sup-0001){ref-type="supplementary-material"}). Concentrations of fibrinogen, however, were increased by 56%.

VKA Intake and Cardiovascular Status in Multivariable Regression Models {#jah33437-sec-0017}
-----------------------------------------------------------------------

In a fully adjusted regression model, controlled for age, sex, and cardiovascular risk factors, the strongest independent associations with VKA use were observed for stiffness index (β=2.54 m/s \[0.41; 4.66\], *P*=0.019), ankle--brachial index (β=−0.03 \[−0.04; −0.01\], *P*\<0.0001), mean intima‐media thickness of the carotid artery (β=0.03 mm \[0.01; 0.05\], *P*=0.0098), LV ejection fraction of the heart (β=−4.02% \[−4.70; −3.33\], *P*\<0.0001), E/E′ (β=0.04 \[0.01; 0.08\], *P*=0.014), and LV mass/height^2.7^ (β=5.34 g/m^2^ \[4.26; 6.44\], *P*\<0.0001). Vascular function measured by flow‐mediated dilatation, reactive hyperemia index, or reflection index was not associated with anticoagulation use (Table [3](#jah33437-tbl-0003){ref-type="table"}).

###### 

Multivariable Linear Regression Models on the Relationship Between Surrogate Parameters of Clinical and Subclinical Cardiovascular Disease and Therapy With VKA

                                                                                                          β‐Estimates for VKA Therapy                                              
  ------------------------------------------------------------- ----------------------------------------- ----------------------------- ------------------------------------------ ----------
  Vasculature                                                   Arterial stiffness                                                                                                 
  Augmentation index, %                                         −2.12 \[−4.61; 0.37\]                     0.095                         −1.23 \[−3.66; 1.20\]                      0.32
  Stiffness index, m/s[b](#jah33437-note-0009){ref-type="fn"}   3.39 \[1.24; 5.54\]                       0.0020                        2.54 \[0.41; 4.66\]                        0.019
  Endothelial function                                                                                                                                                             
  Flow‐mediated dilation, %                                     −0.11 \[−0.75; 0.53\]                     0.73                          0.09 \[−0.55; 0.73\]                       0.79
  log (reactive hyperemia index)                                −0.07 \[−0.13; −0.01\]                    0.014                         −0.05 \[−0.11; 0.01\]                      0.078
  Reflection index                                              −0.87 \[−2.74; 1.00\]                     0.36                          −0.96 \[−2.84; 0.91\]                      0.31
  Endothelial structure                                                                                                                                                            
  Baseline BA diameter, mm                                      0.04 \[−0.03; 0.11\]                      0.27                          0.005 \[−0.07; 0.08\]                      0.90
  Intima‐media thickness, mm                                    0.03 \[0.01; 0.05\]                       0.0048                        0.03 \[0.01; 0.05\]                        0.0098
  Peripheral arterial disease                                                                                                                                                      
  Ankle--brachial index                                         −0.03 \[−0.04; −0.01\]                    0.00012                       −0.03 \[−0.04; −0.01\]                     \<0.0001
  Heart                                                         Cardiac function                                                                                                   
  Diastolic function---log (E/E′‐ratio)                         0.06 \[0.02; 0.09\]                       0.0012                        0.04 \[0.01; 0.08\]                        0.014
  Systolic function---LV ejection fraction, %                   −4.11 \[−4.79; −3.43\]                    \<0.0001                      −4.02 \[−4.70; −3.33\]                     \<0.0001
  Cardiac structure                                                                                                                                                                
  LV mass/height^2.7^, g/m^2.7^                                 6.27 \[5.08; 7.45\]                       \<0.0001                      5.34 \[4.26; 6.44\]                        \<0.0001
  Relative wall thickness                                       3.6×10^−3^ \[−6.2×10^−3^; 13.4×10^−3^\]   0.47                          −2.7×10^−3^ \[−12.3×10^−3^; 6.9×10^−3^\]   0.58

Effect estimates presented are β‐values for VKA use (yes/no) derived from general linear models for each outcome. BA indicates brachial artery; CI, confidence interval; LV, left ventricular; VKA, vitamin K antagonists.

Cardiovascular risk factors are diabetes mellitus, dyslipidemia, hypertension, obesity, smoking, family history of stroke/myocardial infarction, and estimated glomerular filtration rate.

Displayed estimates are given for mean age of 55 years; model was additionally adjusted for age×VKA interaction.

VKA Intake and Humoral Biomarkers in Multivariable Regression Models {#jah33437-sec-0018}
--------------------------------------------------------------------

A significant positive association with anticoagulation therapy was revealed for midregional pro‐adrenomedullin, midregional pro‐atrial natriuretic peptide, and N‐terminal pro B‐type natriuretic peptide as surrogates for the presence of heart failure. hs‐CRP and fibrinogen concentrations were positively linked with anticoagulation use (β=0.31 mg/L \[0.20; 0.43\], *P*\<0.0001 and β=143 mg/dL \[132; 153\], *P*\<0.0001, respectively). Again, as proof of the VKA effect, activity levels of FVIII, von Willebrand factor were positively related with VKA use, whereas it was inversely related with FXI activity and hs‐D‐dimer concentration (Table [4](#jah33437-tbl-0004){ref-type="table"}).

###### 

Multivariable Linear Regression Models on the Relationship Between Humoral Biomarkers and Therapy With VKA

                                                                  β‐Estimates for VKA Therapy                                        
  --------------------------------------------------------------- ----------------------------- ---------- ------------------------- ----------
  Biomarkers of cardiac function                                                                                                     
  log (MR‐proANP), pmol/L                                         0.59 \[0.51; 0.67\]           \<0.0001   0.58 \[0.50; 0.65\]       \<0.0001
  log (MR‐proADM), nmol/L                                         0.22 \[0.18; 0.27\]           \<0.0001   0.18 \[0.14; 0.22\]       \<0.0001
  log (Nt‐proBNP), pg/mL[b](#jah33437-note-0012){ref-type="fn"}   1.93 \[1.66; 2.19\]           \<0.0001   1.90 \[1.63; 2.17\]       \<0.0001
  Biomarkers of coagulation                                                                                                          
  Fibrinogen, mg/dL[b](#jah33437-note-0012){ref-type="fn"}        147 \[136; 158\]              \<0.0001   143 \[132; 153\]          \<0.0001
  F‐VIII, %                                                       15.8 \[8.99; 22.7\]           \<0.0001   13.4 \[6.7; 20.2\]        \<0.0001
  F‐XI, %                                                         −9.01 \[−12.7; −5.30\]        \<0.0001   −9.63 \[−13.31; −5.95\]   \<0.0001
  log (hs‐D‐dimer), μg/L                                          −0.89 \[−1.02; −0.76\]        \<0.0001   −0.92 \[−1.05; −0.79\]    \<0.0001
  log (thrombomodulin), %                                         0.04 \[−0.04; 0.12\]          0.31       0.01 \[−0.07; 0.09\]      0.76
  Tissue factor, %                                                16.9 \[−3.89; 37.7\]          0.11       14.7 \[−6.0; 35.4\]       0.16
  vWF, %                                                          13.4 \[5.9; 20.9\]            0.00047    11.2 \[3.8; 18.7\]        0.0032
  Biomarkers of inflammation                                                                                                         
  log (hs‐CRP), mg/L                                              0.42 \[0.30; 0.55\]           \<0.0001   0.31 \[0.20; 0.43\]       \<0.0001
  IL‐18, pg/mL                                                    23.0 \[−0.91; 46.9\]          0.059      17.9 \[−5.7; 41.5\]       0.14
  IL‐1RA, pg/mL[b](#jah33437-note-0012){ref-type="fn"}            36.0 \[−10.1; 82.2\]          0.13       17.2 \[−26.0; 60.3\]      0.43
  Leukocyte count, /nL                                            0.03 \[−0.001; 0.06\]         0.058      0.01 \[−0.02; 0.04\]      0.39
  MPO, pmol/L                                                     33.9 \[−1.58; 69.4\]          0.061      30.6 \[−5.0; 66.2\]       0.092

Effect estimates presented are β‐values for VKA use (yes/no) derived from general linear models for each outcome. All biomarkers were measured in 5000 participants, except CRP and leukocyte count (available for 15 010 participants). CI indicates confidence interval; hs‐CRP, high sensitivity C‐reactive protein; MPO, myeloperoxidase; Nt‐proBNP, N‐terminal pro B‐type natriuretic peptide; MR‐proADM, midregional pro‐adrenomedullin; MR‐proANP, midregional pro‐atrial natriuretic peptide; VKA, vitamin K antagonists; vWF, von Willebrand factor.

Cardiovascular risk factors are diabetes mellitus, dyslipidemia, hypertension, obesity, smoking, family history of stroke/myocardial infarction, and estimated glomerular filtration rate.

Displayed estimates are given for men; model was additionally adjusted for sex (women)×VKA interaction; the estimates for women have to be corrected by adding the following values: Nt‐proBNP, −0.95; fibrinogen, +39.0; IL‐1RA, +111.

Relationship Between Genetic Variants of VKA Metabolism and Surrogate Markers of CVD {#jah33437-sec-0019}
------------------------------------------------------------------------------------

Table [5](#jah33437-tbl-0005){ref-type="table"} and Table [S4](#jah33437-sup-0001){ref-type="supplementary-material"} display the relationship between systematically selected SNPs associated with warfarin maintenance dose and surrogate markers of CVD. *CYP2C9* polymorphisms mainly affected cardiac structure and function among VKA users. Carriers of the minor SNP allele had increased thrombomodulin levels and lower LV mass/height^2.7^ in VKA users, but not in VKA nonusers. Rs2108622 was significantly correlated with an elevated concentration of fibrinogen in VKA users but not in VKA nonusers. The mutant allele of *CYP4F2* rs2108622 was linked to elevated F‐XI concentrations and increased LV mass/height,^2.7^ both in VKA users and nonusers, with higher estimates in VKA users.

###### 

SNPs Identified in GWAS Catalogue Known to Influence Warfarin Dose Requirements and Their Relationship to Surrogate Parameters of Atherosclerosis

  Selected SNPs From GWAS Catalogue   Chr   Position (Mb)[a](#jah33437-note-0014){ref-type="fn"}   Gene       Tag SNP on Affymetrix 6.0 With *r*²\>0.9   Effect of Minor Allele      Effect Under VKA Use     β Estimate for VKA User[b](#jah33437-note-0015){ref-type="fn"}   Effect Under No VKA Use   β Estimate for VKA Nonuser[b](#jah33437-note-0015){ref-type="fn"}
  ----------------------------------- ----- ------------------------------------------------------ ---------- ------------------------------------------ --------------------------- ------------------------ ---------------------------------------------------------------- ------------------------- -------------------------------------------------------------------
  rs10509680                          10    96734339                                               *CYP2C9*   rs9332245                                  Lower                       Baseline BA diameter ↑   0.153                                                            Baseline BA diameter ↓    −0.057
                                                                                                              dose                                       E/E′ ↓                      −0.230                   E/E′ →                                                           No effect                 
                                                                                                              requirement                                                                                                                                                                                
  rs12777823                          10    96405502                                               *CYP2C9*   n.a.                                       Lower                       Fibrinogen ↑             8.7                                                              Fibrinogen ↑              5.6
                                                                                                              dose                                       Flow‐mediated dilation ↓    −0.44                    Flow‐mediated dilation ↓                                         −0.46                     
                                                                                                              requirement                                Relative wall thickness ↑   0.05                     Relative wall thickness →                                        No effect                 
                                                                                                                                                         Ejection fraction ↑         5.54                     Ejection fraction →                                              No effect                 
                                                                                                                                                         IL‐18 ↑                     100.8                    IL‐18 →                                                          No effect                 
  rs4086116                           10    96707202                                               *CYP2C9*   n.a.                                       Lower                       Baseline BA diameter ↓   −0.144                                                           Baseline BA diameter ↓    −0.034
                                                                                                              dose                                       MR‐proADM ↓                 −0.057                   MR‐proADM ↑                                                      0.013                     
                                                                                                              requirement                                IL‐18 ↓                     −16.6                    IL‐18 ↑                                                          8.4                       
                                                                                                                                                         Ejection fraction ↓         −4.27                    Ejection fraction →                                              No effect                 
                                                                                                                                                         LV mass/height^2.7^ ↑       4.59                     LV mass/height^2.7^ →                                            No effect                 
  rs10871454                          16    31048079                                               *VKORC1*   rs11150604                                 Lower                       Thrombomodulin ↑         0.199                                                            Thrombomodulin ↓          −0.021
                                                                                                              dose                                       LV mass/height^2.7^ ↓       −2.42                    LV mass/height^2.7^ →                                            No effect                 
                                                                                                              requirement                                                                                                                                                                                
  rs2108622                           19    15990431                                               *CYP4F2*   n.a.                                       Higher                      LV mass/height^2.7^ ↑    1.68                                                             LV mass/height^2.7^ ↑     0.48
                                                                                                              dose                                       F‐XI ↑                      5.5                      F‐XI ↑                                                           1.0                       
                                                                                                              requirement                                Fibrinogen ↑                30.47                    Fibrinogen →                                                     No effect                 

BA indicates brachial artery; Chr, chromosome; GWAS, genome‐wide association studies; IL‐18, interleukin 18; LV, left ventricular; MR‐proADM, midregional pro‐adrenomedullin; n.a., not available; SNP, single nucleotide polymorphism.

Based on genome built 105.

Estimated change per allele.

Subgroup Analysis {#jah33437-sec-0020}
-----------------

In order to evaluate the results in a more homogeneous subgroup, linear regression models controlled for age, sex, and traditional cardiovascular risk factors were performed in individuals with atrial fibrillation and a CHA~2~DS~2~‐VASc score of ≥1 only (see Table [S5](#jah33437-sup-0001){ref-type="supplementary-material"} for clinical characteristics). The results in this subgroup confirmed the earlier findings (Table [S6](#jah33437-sup-0001){ref-type="supplementary-material"}): VKA therapy was independently related to LV ejection fraction (β=−2.12% \[−3.85; −0.38\], *P*=0.017), LV mass/height^2.7^ (β=3.61 g/m^2^ \[0.90; 6.31\], *P*=0.0089), midregional pro‐atrial natriuretic peptide (β=0.42 pmol/L \[0.25; 0.60\], *P*\<0.0001), N‐terminal pro B‐type natriuretic peptide (β=1.19 pg/mL \[0.73; 1.65\], *P*\<0.0001), fibrinogen (β=135 mg/dL \[112; 157\], *P*\<0.0001), F‐XI (β=−10.8% \[−17.5; −4.14\], *P*=0.0015), hs‐D‐dimer (β=−1.07 μg/L \[−1.31; −0.84\], *P*\<0.0001), and hs‐CRP (β=0.20 mg/L \[0.01; 0.39\], *P*=0.035). With regard to arterial stiffness, VKA intake showed a similar effect on stiffness index in this sensitivity analysis as was demonstrated in the unrestricted analysis (β=3.45 m/s \[−1.60; 8.50\], *P*=0.18). A further propensity score analysis weighted for traditional cardiovascular risk factors and history of cardiovascular diseases in individuals with atrial fibrillation/venous thromboembolism confirmed the robustness of the observations made in the regression analysis (Table [S7](#jah33437-sup-0001){ref-type="supplementary-material"}). To assess possible effects of the duration of VKA treatment on the interrelation between VKA intake and subclinical CVD phenotypes, data were analyzed stratified by the history of drug intake. In brief, hs‐CRP concentrations were elevated by 11% when comparing patients with VKA treatment \>3 years as opposed to those with shorter treatment. In line with the previous results, arterial stiffness, measured by augmentation index and stiffness index, was higher in individuals with long‐term exposure to VKA compared with those with short‐term exposure, supporting a dose--response relationship (Table [6](#jah33437-tbl-0006){ref-type="table"}). For further evaluation of a time‐dependent, cumulative effect of VKA intake on subclinical phenotypes of CVD, treatment duration was stratified in \<1, 1 to 3, and \>3 years as illustrated in Table [S8](#jah33437-sup-0001){ref-type="supplementary-material"}. In brief, the analysis confirmed a dose‐dependent interrelation between intake of VKA and specific biomarkers identified in the prior analysis (eg stiffness index, E/E′ ratio, and LV mass).

###### 

Surrogate Parameters of Clinical and Subclinical Cardiovascular Disease and Humoral Biomarkers According to History of VKA Treatment Length

                                                               3 Y or Less (N=130)   More Than 3 Y (N=130)
  --------------------------------- -------------------------- --------------------- -----------------------
  Vascular structure and function   Arterial stiffness                               
  Augmentation index, %             14.6 (6.2/29.2)            19.7 (7.6/33.2)       +35%
  Stiffness index, m/s              7.56 (6.12/8.92)           7.89 (6.41/9.58)      +4%
  Endothelial function                                                               
  Flow‐mediated dilation, %         6.21 (3.61/8.99)           5.90 (3.63/8.12)      −5%
  Log (reactive hyperemia index)    0.43 (0.10/0.88)           0.34 (0.15/0.74)      −21%
  Reflection‐index                  66.5 (54.0/77.0)           72.0 (60.3/80.0)      +8%
  Endothelial structure                                                              
  Baseline BA diameter, mm          4.73 (4.08/5.33)           4.95 (4.25/5.33)      +5%
  Intima‐media thickness, mm        0.72 (0.63/0.84)           0.73 (0.68/0.85)      +2%
  Peripheral arterial disease                                                        
  Ankle--brachial index             0.97 (0.89/1.04)           0.97 (0.88/1.07)      0%
  Cardiac structure and function    Cardiac function                                 
  E/E′‐ratio                        8.02 (6.32/10.03)          8.73 (6.80/12.38)     +9%
  Ejection fraction, %              61.1 (55.4/66.4)           60.0 (53.7/65.1)      −2%
  Cardiac structure                                                                  
  LV mass/height^2.7^, g/m^2.7^     45.6 (37.2/54.5)           47.6 (38.9/56.9)      +4%
  Relative wall thickness           0.429 (0.371/0.489)        0.417 (0.365/0.507)   −3%
  Humoral biomarker                 Biomarker of coagulation                         
  Fibrinogen, mg/dL                 506 (438/584)              500 (428/588)         −1%
  Biomarker of inflammation                                                          
  hs‐CRP, mg/L                      2.65 (1.20/5.50)           2.95 (1.30/5.42)      +11%
  Leukocytes, /nL                   7.08 (5.93/8.20)           7.30 (6.19/8.50)      +3%

For continuous variables, data are expressed as median with 25th/75th percentile. The percentage differences represent an increase or decrease going from "VKA use of 3 y or less" to "VKA use of more than 3 y." BA indicates brachial artery; hsCRP, high‐sensitivity C‐reactive protein; LV, left ventricular; VKA, vitamin K antagonists.

Discussion {#jah33437-sec-0021}
==========

The present study investigated, for the first time, the link between the use of VKA and a comprehensive set of clinical and subclinical measures of CVD in a large population‐based sample. The analysis demonstrated a relationship of VKA treatment with increased arterial stiffness, higher LV mass, and decreased cardiac systolic function independent of the clinical profile. Correspondingly, anticoagulation use was also linked with increased concentrations of humoral biomarkers of cardiac function and inflammation. Subgroup analysis confirmed these data: a homogeneous subsample of subjects with atrial fibrillation with indication for oral anticoagulation based on the CHA~2~DS~2~‐VASc score showed consistent results for the comparison of VKA users to anticoagulation‐naïve individuals. As an indicator for a dose--response effect, levels of arterial stiffness and hs‐CRP were higher in long‐term VKA users compared with individuals with shorter intake.

The results from this large population sample are supported by data from the literature: an observational study reported that warfarin administration is associated with a rapid progression of aortic stiffness in patients undergoing hemodialysis.[11](#jah33437-bib-0011){ref-type="ref"} Arterial stiffness is influenced by the calcification of the elastic components of the artery wall, leading to hypertension. In humans, studies of limited sample size have reported an association of VKA treatment with calcification of the coronary arteries.[8](#jah33437-bib-0008){ref-type="ref"}, [12](#jah33437-bib-0012){ref-type="ref"}, [13](#jah33437-bib-0013){ref-type="ref"} Also, carotid intima‐media thickness is known to be correlated with atherosclerotic calcification.[14](#jah33437-bib-0014){ref-type="ref"} Interestingly, in the present analysis anticoagulation therapy remained independently related to higher intima‐media thickness after adjustment for the clinical profile.

Experimental data indicated that VKA may lead to calcification via inhibition of MGP, a vitamin K‐dependent protein produced by vascular smooth muscle cells, which is considered to be a strong inhibitor of vascular calcification.[15](#jah33437-bib-0015){ref-type="ref"} MGP‐knockout mice developed soft‐tissue calcification resulting in vascular stiffening and died of vascular rupture 8 weeks after birth.[16](#jah33437-bib-0016){ref-type="ref"} Furthermore, both valvular and arterial calcification have been reported in animals on warfarin treatment.[17](#jah33437-bib-0017){ref-type="ref"} By contrast, limited data from experimental animal studies have indicated a potentially beneficial effect of novel, direct‐acting anticoagulants on the development and progression of atherosclerosis.[18](#jah33437-bib-0018){ref-type="ref"}, [19](#jah33437-bib-0019){ref-type="ref"}, [20](#jah33437-bib-0020){ref-type="ref"}

Aortic and cardiac valve calcification as well as the abnormal pressure caused by calcification increase cardiac afterload and therefore may promote the development of systolic and diastolic cardiac dysfunction, LV hypertrophy, aortic stenosis, and subsequently congestive heart failure.[21](#jah33437-bib-0021){ref-type="ref"} In the present study, these findings were substantiated by demonstrating an aggravation of cardiac dysfunction in VKA patients compared with the reference group without VKA. Linear regression analyses suggest a link between anticoagulation therapy and an increased LV mass/height^2.7^ ratio, potentially caused by arterial hypertension because of higher stiffness or valve resistance.[22](#jah33437-bib-0022){ref-type="ref"}

The current study demonstrated the presence of elevated concentrations of inflammatory biomarkers (ie hs‐CRP, fibrinogen) in individuals on VKA treatment. Previous reports on the inflammation profile of anticoagulated subjects are rare and rather inconsistent. Studies have demonstrated anti‐inflammatory effects at low‐dose warfarin concentrations in animals[23](#jah33437-bib-0023){ref-type="ref"} and showed little or no effect at the concentration that is used in the clinical setting to reduce hypercoagulability.[24](#jah33437-bib-0024){ref-type="ref"} These studies, however, are prone to methodological limitations including small sample sizes. Importantly, it is well recognized that coagulation factors play a significant role in the process of inflammation and atherosclerosis.[25](#jah33437-bib-0025){ref-type="ref"} The attenuation of protein C has been reported to reduce anti‐apoptotic activity of the endothelial barrier and to promote local inflammation within the arterial wall,[25](#jah33437-bib-0025){ref-type="ref"} which is accompanied, at least to a certain degree, by calcification.[26](#jah33437-bib-0026){ref-type="ref"} In addition, infiltration of vascular tissue is characterized by increased oxidative stress and subsequently by endothelial dysfunction leading to increased vascular stiffness.[27](#jah33437-bib-0027){ref-type="ref"} Coumarin derivatives including phenprocoumon have been shown to act as sepiapterin reductase inhibitors leading to intracellular tetrahydrobiopterin (BH~4~) depletion.[28](#jah33437-bib-0028){ref-type="ref"} Endothelial BH~4~ depletion in turn may reduce vascular nitric oxide production or even cause endothelial nitric oxide synthase uncoupling associated with endothelial dysfunction and therefore higher vascular production of reactive oxygen species within the vascular wall.[29](#jah33437-bib-0029){ref-type="ref"} Thus, the resulting reduction in vascular nitric oxide bioavailability may also contribute to increased vascular stiffness. VKA also inhibit the carboxylation of Gas‐6, which protects vascular smooth muscle cells from calcification by inhibiting apoptosis.[30](#jah33437-bib-0030){ref-type="ref"} This may have contributed to the enhanced inflammation observed in the present study. Therefore, one might speculate that VKA cause inflammation and apoptosis of vascular smooth muscle cells while simultaneously reducing endothelial nitric oxide production, which could potentially accelerate the process of vascular and cardiac damage. It merits consideration that the influence of VKA treatment may affect specific vascular beds differently (eg according to the content of VKA‐dependent extracellular matrix protein GIa), which may also impact on the subsequent clinical outcome.[31](#jah33437-bib-0031){ref-type="ref"} As an interconnecting link, the increased level of systemic inflammation upon VKA intake may serve as a potential explanation for VKA‐induced propagation of (subclinical) atherosclerosis and cardiovascular disease.

Finally, the effect of genetic polymorphisms associated with VKA dosing surrogate markers for prevalent CVD was investigated. Genome‐wide association studies have identified the association of CYP2C9, VKORC1, and CYP4F2 SNPs with stable VKA dosing.[32](#jah33437-bib-0032){ref-type="ref"} Interestingly, comparable effects of gene variants on enzyme activity did not always match with homogeneous effects on cardiac structure and function, and inflammation. Among VKA users and VKA‐naïve subjects, SNPs affecting the VKA dosing translated into different effects on subclinical and humoral markers of CVD. The influence of VKA metabolism indicates that VKA therapy has a link to CVD progression, rather than an underlying CVD. Although these analyses do not provide sufficient evidence to avoid the use of VKA in patients susceptible to deterioration of cardiac and vascular function, the potential implication for individualized antithrombotic therapy merits further investigation, especially in comparison to direct inhibition of FIIa and FXa, respectively.

Limitations {#jah33437-sec-0022}
-----------

There are several limitations that need to be considered when interpreting the data of the present study. First, the cross‐sectional design does not allow for making any inferences about cause and effect. Prospective data covering an adequate period of exposure to VKA is necessary to analyze the effects of VKA on atherosclerosis over time. Second, although a large panel of potential confounders was adjusted for in regression analysis, the possibility that unmeasured confounders might have contributed to the observed findings cannot be excluded. Third, information on serum concentrations of MGP and Gas‐6 were not available for the present study, but rather likely biological sequelae were investigated. Fourth, individuals receiving novel, direct‐acting anticoagulants for oral anticoagulation therapy were not available for comparison at a statistically adequate sample size in the study sample. Fifth, the limited sample size did not allow providing specific subgroup analysis for potentially vulnerable patient populations (eg patients with type 2 diabetes mellitus). Sixth, parts of the findings of the present study confirm prior investigations on the associations of VKA and subclinical markers of CVD. Finally, the results may not be extrapolated to populations of other ethnic backgrounds as allele frequencies of CYP2C9 and VKORC1 vary among ethnic groups.

Conclusions {#jah33437-sec-0023}
===========

In summary, the present investigation indicates an independent association between the use of VKA and surrogate parameters of arterial stiffness, vascular morphology, cardiac structure and function, and inflammation in the population. Given the high coprevalence of oral anticoagulation therapy with (sub)clinical atherosclerosis and the increasing need for antithrombotic agents in the future, these findings may have implications for individually tailored approaches for antithrombotic therapy.
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